Journal article

Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study

Ian Buysschaert, Christophe L Dubois, Joseph Dens, John Ormiston, Stephen Worthleys, Dougal McClean, Jan Paul Ottervanger, Ian Meredith, Neal Uren, William Wijns, Rob Whitbourn, Roxana Mehran, Alexandra J Lansky, Marzena Bichalska, Susanne Meis, Stefan Verheye

EuroIntervention | EUROPA EDITION | Published : 2013


AIMS: To report the three-year clinical outcome of the Axxess™ stent, a nitinol self-expanding Biolimus A9™ eluting stent for treatment of de novo coronary bifurcation lesions. The Axxess stent is a new-generation drug-eluting stent that might offer advantages in terms of improved clinical outcomes and safety profile in bifurcation lesion stenting. METHODS AND RESULTS: The DIVERGE study was a multicentre, prospective, single-arm trial. The primary endpoint was the cumulative rate of major adverse cardiac events (MACE), a composite of all-cause death, myocardial infarction (MI), and ischaemia-driven target lesion revascularisation (TLR) at one, two and three years. Secondary safety endpoints ..

View full abstract